Dian Diagnostics Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018
April 08, 2019 at 01:47 pm EDT
Share
Dian Diagnostics Group Co., Ltd. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was CNY 6,966.857 million compared to CNY 5,004.124 million a year ago. Operating income was CNY 721.397 million compared to CNY 592.902 million a year ago. Net income was CNY 388.608 million compared to CNY 349.592 million a year ago. Basic earnings per share from continuing operations was CNY 0.71 compared to CNY 0.64 a year ago.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
DIAN DIAGNOSTICS GROUP CO.,LTD. 
